BMYBristol-Myers SquibbRunning, no new patients
Effectiveness Study of Nivolumab Compared to Placebo in Prevention of Recurrent Melanoma After Complete Resection of Stage IIB/C Melanoma
Melanoma
3Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +2.6
2 insiders sold shares within a month
Since Sep 9, 2026 · was worth 5, fading over time
Worry score3
Score over time
- Stage
- Phase 3
- Patients
- 790 (final count)
- Started
- Oct 28, 2019
- Main results expected
- Jun 28, 2022
- Fully finished
- Nov 30, 2026
- Results posted
- Jul 27, 2023
What counts as success
The trial's main goal(s), called the “primary outcome.”
Recurrence Free Survival (RFS)
Measured over: From randomization up to the date of first recurrence, new primary melanoma, or death (whatever the cause), whichever occurs first (up to 32 months)
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 2.6, since 2026-09-09, fades (half-life)
Raw record changes
- none yet
Trial ID NCT04099251 · record last updated 2026-08-07 · checked 2026-11-09 15:47 UTC